Beyond Air Inc. $(XAIR)$ has announced its financial results for the fiscal fourth quarter and year ended March 31, 2025. The company reported a 220% increase in annual revenues, rising to $3.7 million from $1.2 million for the previous fiscal year ended March 31, 2024. Despite this significant growth in revenues, Beyond Air reported a net loss attributed to common stockholders of $46.6 million for the year ended March 31, 2025, compared to a net loss of $60.2 million for the previous fiscal year. Looking ahead, Beyond Air expects to report revenues of at least $1.7 million for the quarter ending June 30, 2025, and has introduced revenue guidance of $12 million to $16 million for the full fiscal year 2026. The company has also submitted a PMA supplement for its second-generation LungFit® PH to the FDA and continues to expand its international distribution partnerships, now covering markets representing over 2 billion lives. LungFit® PH is actively shipping to Europe, Australia, and the Middle East. Additionally, Robert Goodman, a seasoned healthcare executive, has been appointed to the company's Board of Directors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.